Loading...
A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph, Nuradh O'Hara, Catherine Choudhury, Ananya Logue, John P Wylie, James P
Joseph, Nuradh
O'Hara, Catherine
Choudhury, Ananya
Logue, John P
Wylie, James P
Citations
Altmetric:
Abstract
Dose escalation has been shown to improve biochemical outcome in localised prostate cancer. An HDR brachytherapy boost is an effective strategy for dose escalation, since it exploits the low α/β ratio in prostate cancer, allowing the delivery of a high biological dose to the tumour. We sought to evaluate the biochemical disease free survival in patients with intermediate and high risk localised prostate cancer treated with EBRT plus HDR brachytherapy as a boost, in our institution.
Affiliation
Description
Date
2016-10-28
Publisher
Collections
Keywords
Type
Article
Citation
A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. 2016, Radiother Oncol